Nuveen LLC Takes Position in LeMaitre Vascular, Inc. $LMAT

Key Points

• Nuveen LLC has acquired a new position in LeMaitre Vascular, purchasing 55,194 shares valued at approximately $4.63 million, representing about 0.24% of the company's stock.
• CEO George W. Lemaitre sold 100,000 shares of the company for $9.35 million, reducing his ownership by 5.47% to 1,727,003 shares.
• Analysts have set a consensus target price of $97.60 for LeMaitre Vascular, with ratings ranging from "Buy" to "Hold."

Nuveen LLC bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 55,194 shares of the medical instruments supplier's stock, valued at approximately $4,631,000. Nuveen LLC owned approximately 0.24% of LeMaitre Vascular as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Opal Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $26,000. NBC Securities Inc. acquired a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $36,000. US Bancorp DE boosted its position in shares of LeMaitre Vascular by 36.0% during the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after acquiring an additional 368 shares in the last quarter. Blueshift Asset Management LLC acquired a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $232,000. Finally, Cetera Investment Advisers boosted its position in shares of LeMaitre Vascular by 11.5% during the 4th quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock valued at $254,000 after acquiring an additional 284 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,727,003 shares of the company's stock, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bridget A. Ross sold 2,500 shares of the business's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $274,104. This represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 120,815 shares of company stock valued at $11,280,206. Insiders own 9.50% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Cantor Fitzgerald lifted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, LeMaitre Vascular currently has a consensus rating of "Hold" and a consensus target price of $97.60.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $95.28 on Wednesday. The firm has a market cap of $2.16 billion, a PE ratio of 46.25, a price-to-earnings-growth ratio of 2.51 and a beta of 0.79. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The company's 50-day moving average price is $86.58 and its two-hundred day moving average price is $86.37.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same period in the previous year, the firm posted $0.52 earnings per share. The company's revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. LeMaitre Vascular's payout ratio is currently 38.83%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.